Health technology innovation is advanced from investors deciding to fund pipeline assets, yet investors are a stakeholder group less familiar to the health economics and outcomes research (HEOR) community. How do investors make decisions regarding pipeline assets? And how can HEOR methods and approaches better reflect investor priorities? In this qualitative seminar, Dr. Xie will describe how investors make decisions about pipeline assets based on firsthand observations, discuss how his experiences have changed his perspectives on some of the widely accepted and debated issues in HEOR, and explore areas of improvement for HEOR approaches to better reflect real-world market dynamics.
Richard Xie is a Senior Health Economist at RA Capital. In his current role, Richard is spearheading the effort to communicate investors’ and portfolio companies’ value proposition to payors, policymakers, and society through comprehensive value assessment practices and generalized cost-effectiveness analysis (GCEA) method development. Prior to joining RA, Richard served as Director of Research at the Innovation and Value Initiative (IVI), a non-profit research organization dedicated to advancing methods and practices of health technology assessment. At IVI, he managed a portfolio of research projects and worked with leading researchers and multi-stakeholder advisory committees. These research projects tested and operationalized novel approaches in stakeholder engagement, patient preference, economic modeling, and health equity. Before IVI, he was a consultant at the Analysis Group, assisting clients in the pharmaceutical industry with their value demonstration efforts at product launches. Richard earned his doctorate in economics from the University of Southern California and his bachelor's and master's degrees from New York University.
